According to the Zhitong Finance APP, on July 27th, AbbVie (ABBV.US) announced that the European Commission has approved Skyrizi (risankizumab) for the treatment of moderate to severe active ulcerative colitis (UC) adult patients who have an inadequate response to conventional therapy or biological products, lose response or are intolerant. This is the fourth indication for which Skyrizi has been approved in the European Union.

Skyrizi is a humanized, IgG1 subtype monoclonal antibody that selectively antagonizes IL-23 by binding to the p19 subunit of IL-23. IL-23 is a cytokine associated with inflammation and is believed to be associated with many chronic immune diseases. Prior to this, Skyrizi had received three approved indications from the European Union, including Crohn's disease, moderate to severe plaque psoriasis, and adult active psoriatic arthritis.